Leukemia Lymphoma Evaluation Non CSF
Abbrev Code: | FLOLL | ||
Order Code: | LAB501 | Order Name: | Leukemia Lymphoma Evaluation Non CSF |
Order Instructions: | Please remember to order surgical pathology consultation and morphologic studies as clinically indicated. For CSF specimens order Leukemia Lymphoma Evaluation, CSF | ||
Synonyms: | Acute Leukemia Immunophenotyping; Chronic Leukemia Immunophenotyping; Leukemia Cell Surface Markers; ALL Immunophenotyping; AMML Immunophenotyping; AML Immunophenotyping; CML-BC Immunophenotyping; CLL Immunophenotyping; Lymphoma Cell Surface Markers; Multiple Myeloma; TCRcB1 (replaces TCR V Beta Repertoire); LGL; NK Cells; CD49d; Flow Cytometry; Hairy Cell Leukemia; Acute Lymphoid Leukemia; Acute Myeloid/Monocytic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia (Blast Crisis); Large Granular Lymphocytes; Natural Killer Disorders; TdT (Terminal Deoxynucleotidyl Transferase); MRD Analysis by Flow Cytometry; KIR by Flow Cytometry; V Beta Analysis by Flow Cytometry; Lymphoma Workup Surgical Pathology; Immunophenotyping Profile | ||
Methodology: | Multi-color immunofluorescence and flow cytometry | ||
CPT Codes: | 88184 x1, 88185 x1, 88187 x1, 88188 x1, 88189 x1 | ||
Test Includes: | Specific combination of monoclonal antibodies which may include: Characterization of B or T cell malignant lymphomas, B lymphocyte markers including kappa and lambda, HLA-DR, monocytic, myeloid, and/or pan histiocytic/monocytic markers, T lymphocyte markers, plasma cell markers, natural killer markers Tdt, MPO, CD49d, and interpretation of results by pathologist. | ||
Turnaround Time: | Performed Mon-Fri 08:00-17:00 and on Saturday before noon. Results are reported within 1-3 business days. | ||
Special Instructions: | Provide diagnosis, age, collection date, and time. Samples will be tested Mon-Fri 08:00-17:00 and on Saturday before noon. Samples are received in the Core lab when the Flow Cytometry lab is not staffed. Contact the IFC laboratory at 612-273-5248 for further information. If testing is needed outside of scheduled hours, contact the hematopathology fellow. | ||
Compliance: | This test was developed and its performance characteristics determined by University of Minnesota Medical Center, Fairview Clinical Laboratories. It has not been cleared or approved by the US Food and Drug Administration. FDA does not require this test to go through premarket FDA review. This test is used for clinical purposes and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical testing. |
Collection Instructions
Specimen: | Blood, involved bone marrow, vitreous fluid or cellular body fluid, or fresh tissue. |
Optimal Volume: | 8 mL blood; 5 mL involved bone marrow, 0.5 mL vitreous fluid, 20 mL cellular body fluid, or 0.5 cm^3 fresh tissue |
Minimum\Peds Volume: | 2 mL blood; 2 mL involved bone marrow, 0.5 mL vitreous fluid, 5 mL cellular body fluid, or 0.5 cm^3 fresh tissue |
Container: | Purple (EDTA) Alternate Containers: Container, Tissue, sterile, See Collection Instructions |
Collection Instructions: |
Collect all specimens aseptically.
|
Causes for Rejection: |
Improper specimen collection or handling, clotted specimen, specimens received >48 hours after collection, formalin-fixed tissue, frozen specimens.
|
Processing and Shipping
Specimen Processing: | Do not centrifuge. Store in refrigerator. Contact IFC Laboratory prior to sending specimen. |
Shipping Instructions: | Ship at room temperature. Must arrive within 24 hours. |
Test Performed at or Referral Lab | UM Flow Cytometry (W) (UMMC East Bank) |
Interpretive
Reference Range: |
By report
|
Use: | Differentiate lymphoma from other cancers and non-malignant processes such as lymphoid hyperplasia. Evaluation of lymphocytosis and identification of lymphoproliferative disorders of blood and bone marrow. Identify various types of malignant lymphoma (B cell versus T cell) and provide immunophenotypic subclassification for many lymphoproliferative disorders (hairy cell leukemia, chronic lymphocytic leukemia, mantle cell lymphoma). Differentiate lymphoma and acute leukemia. Distinguish acute myeloid leukemia (AML) from acute lymphoblastic leukemia (ALL). Subtype ALL into B-cell ALL or T-cell ALL. Monitor for minimal residual disease in ALL. Identify monoclonal plasma cells.
The sensitivity of this assay depends on the immunophenotype of the population, the specimen (blood vs. bone marrow vs. tissue vs. CSF), the number of events collected, and the presence or absence of background non-neoplastic cells. Sensitivities listed are general guidelines.
|
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 759"